- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01564381
Effects of Resveratrol Supplements on Vascular Health in Postmenopausal Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cardiovascular disease is the leading cause of morbidity and mortality in the United States. To reduce the risk of cardiovascular disease (CVD) and its associated health care costs, nutrition and health recommendations strongly advocate the consumption of a diet rich in fruits and vegetables. In addition to essential vitamins and minerals, fruits and vegetables contain a number of bioactive compounds that may be involved in vascular function.
The "French Paradox" refers to diet patterns that, despite being high in saturated fat, are associated with a relatively low cardiovascular risk. An important aspect of many of the diets that were identified in the French Paradox studies is a significant intake of wine, particularly red wine, which can contain an array of phytochemicals that have been postulated to improve cardiovascular health. A polyphenolic that has received particular attention is this regard is resveratrol.
The stilbene resveratrol is found predominately in red grapes, red wine, peanuts and some berries, and it has been touted in the popular press for its potential health-promoting benefits. Emerging evidence suggests a role for resveratrol in the protection against numerous degenerative health problems including CVD and certain cancers, diabetes and some forms of neurodegeneration.
The amount of resveratrol in most foods is very low; thus obtaining the amounts of this compound that have been associated with improved health in animal models is difficult for humans. ResA is a product produced using patented technology that physically binds resveratrol to arginine, creating a novel conjugate. In the preliminary studies the ResA conjugate produced higher peak plasma levels, as well as total plasma levels that persist for a longer period of time when fed to rats. Whether similar results would occur in humans, and the extent to which increasing blood resveratrol concentration can be associated with positive cardiovascular effects in an at-risk population is the subject of this project.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Davis, California, United States, 95616
- University of California, Davis - Ragle Human Nutrition Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 50 to 70 years of age
- Lack of menses in the last year and FSH 23-116.3 mlU/mL
- Subject is willing and able to comply with the study protocols.
- Subject is willing to consume resveratrol supplements/placebo capsules on three separate occasions.
- BMI 18.5-34.9 kg/m2
- Weight ≥ 110 pounds
- LDL-C ≥ 130 mg/dL
Exclusion Criteria:
- BMI ≥ 35 kg/m2
- Self reported use of anticoagulation agents including NSAIDs
- Self reported use of oral cortisone or other immunosuppressive agents,
- Self reported underlying neoplasia or immunological disease
- Food faddists or those taking a non-traditional diet
- Self reported physical activity restricted or reduced due to chronic health conditions
- Self reported diabetes
- Blood pressure ≥ 140/90 mm Hg
- PFA-100 readings 10 % outside of normal reference range (normal reference range for ADP-Collagen: 71-118 sec; Epinephrine-Collagen: 94-193 sec).
- Self reported renal or liver disease
- Self reported heart disease, which includes cardiovascular events and stroke
- Self reported Cushing's syndrome
- Self reported chronic/routine high intensity exercise
- Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT
- Abnormal Liver, CBC or Chemistry panels (laboratory values outside the reference range) if determined to be clinically significant.
- Self reported cancer within past 5 years
- Self reported history of psychiatric disorders i.e. schizophrenia or bi-polar or depression treated with antidepressants within the last 1 year.
- Self reported use of MAOI inhibitor within the last 1 year (e.g. phenelzine (Nardil), tranylcypromine (Parnate), etc)
- Self reported malabsorption (e.g. difficulty digesting or absorbing nutrients from food,
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Resveratrol
The capsules will contain 90mg of resveratrol.
|
90mg of resveratrol.
|
Experimental: ResA
ResA is a product produced by using patented technology that physically binds resveratrol to arginine, creating a novel conjugate.
The capsules will contain 90mg of resveratrol.
|
90mg of resveratrol conjugated with arginine.
|
Placebo Comparator: Placebo
The placebo will be cellulose.
|
Made up of cellulose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioavailability of a novel formulation of resveratrol (ResA) compared to a standard resveratrol supplement
Time Frame: up to 2 hour after consumption
|
We will assess metabolites concentrations of resveratrol and ResA in plasma via HPLC method.
|
up to 2 hour after consumption
|
Change in vascular function in response to ResA compared to native resveratrol
Time Frame: up to 2 hours after consumption
|
We will assess changes in vascular function measured by peripheral arterial tonometry.
|
up to 2 hours after consumption
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in platelet reactivity in response to ResA intake
Time Frame: 1 hour after consumption
|
We will assess platelet function in response to ADP, collagen and arachidonic acid as measured by platelet aggregometer.
|
1 hour after consumption
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert M Hackman, PhD, University of California, Davis
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 270881
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on Resveratrol
-
University at BuffaloKaleida HealthTerminatedObesity | Insulin Resistance | Type 2 DiabetesUnited States
-
Jupiter Orphan Therapeutics Inc.National Institute on Aging (NIA)CompletedPharmacokinetics | Food-drug Interaction | SafetyUnited States
-
MaineHealthAmerican Heart AssociationActive, not recruitingCoronary Artery Disease | Diabetes Mellitus, Type 2United States
-
Bernard FiorettiCompleted
-
Maastricht University Medical CenterDSM Nutritional Products, Inc.Completed
-
Albert Einstein College of MedicineAmerican Diabetes AssociationCompletedImpaired Glucose ToleranceUnited States
-
Federal University of Rio Grande do SulCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Completed
-
University of FloridaCompleted
-
Khoo Teck Puat HospitalNational Medical Research Council (NMRC), SingaporeCompleted
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedCoronary Artery Disease | Blood Pressure | Heart Rate | Autonomic Nervous System DiseaseBrazil